Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Monday, June 29

OSTER SESSIONS Track BI12196-12221

12196 Persistent or relapsing oral candidiasis as an indicator of HIV disease
in children
Gareth Tudor-Williams*; Shunmay Yeung; D. York; R. Booy;
D. Wilkinson, UK
12197 Treatment of primary HIV-infection with nelfinavir,zidovudine,
and lamuvidine
Frederick Hecht*; D. Smith; D. Cooper; R. Anderson; A. Peterson;
JO. Kahn, USA
12198 Double nucleoside analog therapy in patients with acute/primary
HIV-infection
lan Woo*; D. Rouleau; V. Montessori; M. Whaley;.S.G. Montaner;
B. Conway, Canada
12199 Long term evaluation of triple therapy administered since primary
HIV-l-infection (PHI)
Alain M. Lafeuillade*; C. Poggi; L. Chollet; A. Djediouane; N. Profizi,
France
12200 Effect of different combinations of antiretrovirals (AZT + ddl vs. AZT +
3TC + indinavir) on T cell function and apoptosis in early HIV-infection
Stefania Piconi*; Daria Trabattoni; P. Bonfanti; L. Cremoni; P. Fortuna;
L. Colombo; F. Milazzo, Italy
12201 Mutations conferring resistance to protease inhibitors in naive patients
at the time of primary infection
Carlo Federico Perno*; Alessandra Cenci; CF. Perno; A. Bertoli; F. Erba;
A. Mari; F. Amati; E. Conti; M. Clementi; S. Menzo; A. Lazzarin;
G. Tambussi; R. Cali0, Italy
12202 Clinical features of Acute Retroviral Syndrome in La Plata, Argentina
Jorge M. Contarelli*; M.G. Michaan; L.I. Massera; G.E. Alberich;
S. Cabrera; M. Garcia; C. Costanzo, Argentina
12203 ACTG 364:Virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV)
in combination with new nucleoside analogs in nucleoside experienced
subjects
Mary Albrecht*; D. Katzenstein; R.J. Bosch; S.H. Liou; S.M. Hammer, USA
12204 Combination abacavir (1592, ABC)/amprenavir (141 W94) therapy in
HIV-1 infected antiretroviral naive subjects with CD4+ counts 400 cells/
ml and viral load 5000 copies/ml
Pierre-Alexandre Bart*; G.P. Rizzardi; S. Gallant; P. Meylan; W. Spreen;
H. McDade; U.K. Pantaleo, Switzerland
12205 Salvage of multi-drug resistant HIV-infection with D4T/3TC/
hydroxyurea
Steven Miles*; R.E. Winters; P. Ruane, USA
12206 Relationship between delavirdine (DLV) plasma levels,HIV RNA responses
and DLV resistance during combination therapy with zidovudine (ZDV),
and didanosine (ddl)
Brigette Griffit*; G. Morse; L. Demeter; R. Bassett; M. Hughes;
G. Friedland; ACTG 261 Protocol Team, USA
12207 Phase II Study of ritonavir-nelfinavir Combination Therapy: An Update
Joel Gallant*"; M. Health-Chiozzi; R. Anderson; C. Fields; C. Flexner, USA
12208 Selection of FTC dose-based on viral kinetics and pharmacokinetics in an
accelerated clinical trial design
John Delehanty*; James Kahn; M. Thompson; D. Mildvan; J. Pottage;
D. Shepp; J. Delehanty; C. van der Horst, USA

12209 Tolerance and acceptability of vaginal cleansing with benzalkonium
chloride in HIV-infected African pregnant women. 1996-1998 - ANRS
049b clinical trial
Philippe Msellati*; N. Neda; F. Dabis; C. Welffens-Ekra; P. Van De Perre;
V. Leroy; L. Mandelbrot, Cote d'lvoire, Burkina Faso, France
12210 Activity of abacavir (1592, ABC) combined with protease inhibitors (PI)
in therapy naive patients
Dennise Kelleher*; John Mellors; M. Lederman; D. Haas; E. Cooney;
J. Horton; J. Stanford; R. Haubrich, USA
12211 Oral PMPA Prodrug: Relationship between clinical pharmacokinetics,
safety and anti-HIV activity
Kenneth C. Cundy*; S. Safrin; R. Coleman; H.S. Jaffe, USA
12212 Abacavir (1592, ABC) in protocol CNAB 2002, provides effective, longterm, 72 week, artfor patients on triple therapy regimens
Schlomo Staszewski* C. Katlama; T. Harrer; P. Massip; P. Yeni;
A. Cutrell;H.M. Steel, Germany
12213 Early and sustained changes in lymphoctye sub-populations during
abacavir (ABC) and PI therapy
Dennis Kelleher*; Michael Lederman; J. Mellors; D. Haas;
E. Cooney; J. Horton; J. Stanford; R. Haubrich, USA
12214 A second generation non-nucleoside reverse transciptase inhibitor
(S-1153) forthe treatment of HIV-infection: A phase I study
BruceJ. Dezube*; Mark S. Jacobs; G. Leoung; T. Fujiwara; J.A. Proper;
B. Anderson; J. Carpenter; TA. Dahl, USA
12215 Early intervention with maximally suppressive antiretroviral therapy
lowers CD8 counts toward the normal range
Alan L. Landay*; M. Agnoli; M. Czerniewski; J. Spritzler; J. Pottage, USA
12216 Preliminary clinical safety and pharmacokinetics profile
of (+) calanolide A - a naturally occurring NNRTI
Ze-QiXu*; T. Creagh; J. Giltner; J. Ruckle; P. Frank; D. Tolbert;
M.T. Flavin, USA
12217 Nevirapine/lamivudine drug-drug interaction study in HIV-infected
patients
Gerhard Leitz*; M. Lamson; D. Lionetti; J. Sabo; M. Myers, USA
12218 The pharmacokinetic (PK) interactions of nevirapine (NVP) and
ketoconazole (Keto)
Michael Lamson*; Patrick Robinson; M. Lamson; M. Gigliotti;
M. W. Myers, USA
12219 Interim analysis of plasma viral burden reductions and CD4 increases in
HIV-1 infected patients with Rescriptor (DLV)+ Retrovir (ZDV)+ Epivir
(3TC)
Stephen Green*; M.F. Para; P.W. Daly; W. W Freimuth; L.D. Getchel;
C.A. Greenwald; L.K. Wathen, USA
12220 CombivirT (lamivudine (3TC) 150 mg/zidovudine (ZDV) 300 mg) given
BID plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV
200 mg TID Plus a PI
Mark Shaefer*;J. Eron; E. Yetzer; R Ruane;S. Becker; G. Sawyerr;
N. Graham; M. Shaefer, USA
12221 Saquinavir/ritonavir may have better antiviral efficacythan either
ritonavir or indinavir in HIV-infected antiretroviral naive patients
Court Pedersen*; J. Gerstoft; J.O. Lunnogren; L. Mathiesen; 0. Kirk;
H. Nielsen; T. Katzenstein, Denmark

30

12th World AIDS Conference Geneva